Tislelizumab combined with anlotinib and chemotherapy (XELOX) in the treatment of advanced gastric carcinoma: Preliminary results of a single-arm, open-label phase I/IIa trial (TALENT study).

被引：0
|
作者：
Chen, Xiaofeng
Wang, Deqiang
Yuan, Yuan
Tang, Jie
Guo, Fen
Chen, Yizhang
Ding, Junli
Hong, Tingting
Lu, Binbin
Li, Wei
Wang, Rong
Tian, Yitong
Pan, Lanlan
Zhang, Jiaguang
Zhang, Xinyi
Xu, Tongpeng
Xu, Hao
Shu, Yongqian
机构：
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Peoples R China
[2] Jiangsu Univ, Affiliated Hosp, Canc Therapy Ctr, Dept Med Oncol, Zhenjiang, Jiangsu, Peoples R China
[3] Xuzhou Cent Hosp, Xuzhou, Jiangsu, Peoples R China
[4] Jiangsu Peoples Hosp, Liyang Branch, Dept Oncol, Liyang, Peoples R China
[5] Suzhou Municipal Hosp, Dept Oncol, Suzhou, Peoples R China
[6] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Peoples R China
[7] Nanjing Med Univ, Affiliated Wuxi Peoples Hosp, Wuxi, Jiangsu, Peoples R China
[8] Jiangnan Univ, Affiliated Hosp, Wuxi, Jiangsu, Peoples R China
[9] Nanjing Med Univ, Affiliated Hosp 2, Dept Med Oncol, Nanjing, Peoples R China
[10] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China
[11] Nanjing Med Univ, Affiliated Hosp 1, Dept Gen Surg, Nanjing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
396
引用
收藏
页码：396 / 396
页数：1
相关论文
共 50 条
  • [1] Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study.
    Luo, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Kjetil Boye
    Alessandra Longhi
    Tormod Guren
    Susanne Lorenz
    Stine Næss
    Michela Pierini
    Ingeborg Taksdal
    Ingvild Lobmaier
    Marilena Cesari
    Anna Paioli
    Ayca M. Løndalen
    Elisabetta Setola
    Ivar Hompland
    Leonardo A. Meza-Zepeda
    Kirsten Sundby Hall
    Emanuela Palmerini
    Cancer Immunology, Immunotherapy, 2021, 70 : 2617 - 2624
  • [3] Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
    Boye, Kjetil
    Longhi, Alessandra
    Guren, Tormod
    Lorenz, Susanne
    Naess, Stine
    Pierini, Michela
    Taksdal, Ingeborg
    Lobmaier, Ingvild
    Cesari, Marilena
    Paioli, Anna
    Londalen, Ayca M.
    Setola, Elisabetta
    Hompland, Ivar
    Meza-Zepeda, Leonardo A.
    Hall, Kirsten Sundby
    Palmerini, Emanuela
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2021, 70 (09) : 2617 - 2624
  • [4] Erdafitinib in Asian patients with advanced solid tumors: an open-label, single-arm, phase IIa trial
    Park, Joon Oh
    Feng, Yin-Hsun
    Su, Wu-Chou
    Oh, Do-Youn
    Keam, Bhumsuk
    Shen, Lin
    Kim, Sang-We
    Liu, Xiufeng
    Liao, Huimin
    Qing, Min
    Zhang, Chong
    Qian, Jiaqi
    Tang, Xiaodan
    Li, Peng
    Triantos, Spyros
    Sweiti, Hussein
    BMC CANCER, 2024, 24 (01)
  • [5] Neoadjuvant chemoradiotherapy (nCRT) combined with sequential tislelizumab for resectable esophageal squamous cell carcinoma (ESCC): Preliminary results of a single-arm, open-label phase Ib trial (CRIS)
    Jiang, Youhua
    Qiu, Guoqin
    Li, Jianqiang
    Wang, Jiangfeng
    Wang, Changchun
    Wu, Jie
    Cheng, Lei
    Zheng, Yuanda
    Ruan, Rongwei
    Song, Ge
    Ye, Xuemei
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] A prospective single-center, single-arm, open-label, phase II study of sintilimab and anlotinib combined with chemotherapy in neoadjuvant treatment of resectable esophageal cancer
    Duan, Hongtao
    Wang, Zhaoyang
    Cao, Lili
    Zhu, Yifang
    Tong, Liping
    Yan, Xiaolong
    THORACIC CANCER, 2024, 15 (19) : 1471 - 1476
  • [7] Toripalimab combined with bevacizumab and chemotherapy for refractory, recurrent or metastatic cervical cancer: preliminary results of a single-arm, open-label, phase II trial
    Peng, Peng
    Yao, Hairong
    Liu, Dantong
    He, Yonglan
    Liu, Shikai
    Xiang, Yang
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S29 - S29
  • [8] Anlotinib in patients with recurrent advanced cervical cancer: A prospective single-arm, open-label, phase. trial.
    Wu, Xiaohua
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [9] Anlotinib in Chinese Patients With Recurrent Advanced Cervical Cancer: A Prospective Single-Arm, Open-Label Phase II Trial
    Zhu, Jun
    Song, Chunyan
    Zheng, Zhong
    Xia, Lingfang
    Chen, Yanqiong
    Ke, Guihao
    Wu, Xiaohua
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [10] Update results of anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial
    Zhang, Y-F.
    Li, X-B.
    Hong, Y-G.
    Li, X-M.
    Liang, W-M.
    Zheng, Z-X.
    Yang, G-Y.
    Wen, Y-Y.
    Cao, H.
    Wu, W-L.
    Su, W-Z.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1120 - S1120
12345